Format

Send to

Choose Destination
See comment in PubMed Commons below
Eur Arch Otorhinolaryngol. 2013 Sep;270(10):2763-7. doi: 10.1007/s00405-013-2598-6. Epub 2013 Jul 12.

Management of intractable epistaxis in patients who received radiation therapy for nasopharyngeal carcinoma.

Author information

1
The Department of Otolaryngology Head and Neck Oncology, People's Hospital of Guangxi Zhuangzhu Regional National Autonomy, Nanning, China. jake1976@163.com

Abstract

To report clinical manifestations, bleeding point localization, and outcomes of management in 16 patients with 16 instances of intractable epistaxis after radiation therapy for nasopharyngeal carcinoma. Retrospective chart review of 16 patients with nasopharyngeal carcinoma (mean age 52.06 ± 14.37 years) with 16 instances of intractable epistaxis during the past 5 years, whose diagnosis was confirmed by angiography (n = 10) or MRI/CT imaging studies and clinical manifestations (n = 6). The mean radiation dose to the affected carotid artery was 101.37 ± 34.85 Gy. Bleeding points were detected in the internal carotid artery (n = 8) or external carotid artery (n = 8). Detachable balloons were used in one affected artery for vascular occlusion; six were treated using an absorbable gelatin sponge (n = 4) or microcoils (diameter 1 mm) (n = 2). Endovascular embolization was successful in seven radiation carotid blowout syndromes with cessation of hemorrhage. One patient underwent external carotid artery ligation and one patient recovered without treatment. The clinical follow-up was 3 months. Therapeutic endovascular embolization of intractable epistaxis is both efficient and safe. It should be considered as the primary treatment modality in intractable epistaxis of nasopharyngeal carcinoma.

PMID:
23846664
PMCID:
PMC3758511
DOI:
10.1007/s00405-013-2598-6
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer Icon for PubMed Central
    Loading ...
    Support Center